Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
MedImmune signs with Infinity
September 4, 2006
| A version of this story appeared in
Volume 84, Issue 36
MedImmune and Infinity Pharmaceuticals will collaborate to develop small-molecule cancer drugs targeting heat shock protein 90 (Hsp90) and the Hedgehog signaling pathway. Infinity will receive a $70 million up-front fee in exchange for shared rights to its Hsp90 and Hedgehog pathway product development programs, and it could receive an additional $430 million in milestones as products progress toward commercialization. The deal includes IPI-504, an Hsp90 inhibitor that is in Phase I studies for multiple myeloma and gastrointestinal tumors. The companies plan to initiate clinical testing of an oral formulation of IPI-504 in the next 12-18 months.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter